ClinicalTrials.Veeva

Menu

Metformin In Prevention of Lupus Nephritis

Shanghai Jiao Tong University logo

Shanghai Jiao Tong University

Status and phase

Unknown
Phase 4

Conditions

Lupus Nephritis

Treatments

Drug: Metformin

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

Lupus nephritis (LN) is a main manifestation of systemic lupus erythematosus (SLE), which will largely effect the prognosis of SLE patients. Our previous 10-year data showed that the development of LN is most common in the first year of SLE, occupying about 17%. And our group has established a prediction model to predict the 1-year probability of LN for SLE patients without renal involvement. Our previous proof-of-concept trial and multicenter, randomized, double-blind, placebo-controlled trial indicated that metformin seemed to have potential to reduce the new-onset of LN in SLE patients (Unpublished data, in review). So the investigators tried to illustrate whether metformin has effect to prevent the development of lupus nephritis in high risk SLE patients based on LN prediction model.

Enrollment

30 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • New-onset of SLE (within 1 year)
  • Meet the 1997 ACR criteria of SLE
  • 1-year risk of developing LN higher than 50% based on LN prediction model.
  • All the patients received standard care of therapy. (mycophenolate/azathioprine/cyclosporin/tacrolimus/methotrexate/leflunomide were allowed).
  • Sign the informed consent.

Exclusion criteria

  • Patients with kidney involvement at screening were excluded
  • Patients with severe SLE were excluded, such as neuropsychiatric and cardiac involvement
  • Cyclophosphamide or biologics were not allowed.
  • Alanine aminotransferase (ALT)/ aspartate aminotransferase (AST) > 2 times upper normal limits; creatinine clearance rate < 60ml/min;
  • Previous exposure of metformin within 30 days before screening; or previous history of intolerant to metformin;
  • Patients who diagnosed of diabetes mellitus;
  • Pregnancy or lactation.

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

30 participants in 2 patient groups, including a placebo group

Metformin
Active Comparator group
Treatment:
Drug: Metformin
Placebo
Placebo Comparator group
Treatment:
Drug: Metformin

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems